Deal covers four programs targeting autoimmune and inflammatory diseases.

GlaxoSmithKline and Dynavax Technologies have partnered to discover, develop, and commercialize inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses, according to the companies.

Under the terms of the alliance, Dynavax will receive an initial payment of $10 million for which GSK will receive an exclusive option over four programs targeting autoimmune and inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis.

Dynavax is to conduct research and early clinical development in up to four programs and is eligible to receive future potential development and commercialization milestones totaling approximately $200 million per program. GSK can exercise its exclusive option to license each program upon achievement of proof-of-concept or earlier upon certain circumstances. After exercising its option, GSK will carry out further development and commercialization of these products. Dynavax will receive tiered, up to double-digit royalties on sales and has retained an option to codevelop and copromote one specified product.

Previous articleNovo Nordisk Taps VLST to Build Programs in Autoimmunity and Inflammation
Next articleSenetek Acquires Rights to RNAi Technology from Polish Institute